¼¼°èÀÇ ÀÇ»ç Áø·á½Ç Áø´Ü ½ÃÀå
Physician Office Diagnostics
»óǰÄÚµå : 1793718
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 299 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀÇ»ç Áø·á½Ç Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â±îÁö 2¾ï 3,650¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 1,590¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀÇ»ç Áø·á½Ç Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 2¾ï 3,650¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 12.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Point-of-Care °Ë»ç ±â±â´Â CAGR 14.6%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 1,410¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÓ»óÈ­ÇÐ ºÐ¼®±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 10.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 3,160¸¸ ´Þ·¯, Áß±¹Àº CAGR 17.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀÇ»ç Áø·á½Ç Áø´Ü ½ÃÀåÀº 2024³â¿¡´Â 3,160¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2024³âºÎÅÍ 2030³â±îÁö CAGR 17.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 5,060¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 9.0%¿Í 11.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 10.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀÇ»ç Áø·á½Ç Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿Ö ÀÇ·á±â°ü°ú ȯÀÚµé »çÀÌ¿¡¼­ ³»¿ø Áø´ÜÀÌ ¼±È£µÇ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ÀÇ»ç Áø·á½Ç Áø´ÜÀº Á¤±âÀûÀÎ Áø·á ½Ã ½ÃÇàµÇ´Â ´Ù¾çÇÑ °Ë»ç¸¦ Æ÷°ýÇÏ¿© Àû½Ã¿¡ Áø´Ü ¹× Ä¡·á °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. Ç÷¾×°Ë»ç, ¼Òº¯°Ë»ç, ½ÉÀüµµ, ¿µ»ó Áø´Ü, ½Å¼ÓÇ׿ø°Ë»ç, ÇöÀåÁø´ÜºÐ¼®±â µîÀÌ Æ÷ÇԵ˴ϴÙ. ÇöÀå Áø´ÜÀÇ ÆíÀǼºÀº ÀÓ»ó È¿À²¼º, ȯÀÚ ¼øÀÀµµ, Áø´Ü ¼Ò¿ä ½Ã°£À» Çâ»ó½Ãŵ´Ï´Ù.

´ç´¢º´, È£Èí±â °¨¿°, ½ÉÇ÷°üÁúȯ, ¼ºº´ µîÀÇ Áø´Ü µµ±¸¿¡ ÅõÀÚÇÏ´Â ÀÇ»çµéµµ ´Ã°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ÀÏÂ÷ Áø·á ¹× ÀÀ±Þ ÀÇ·á ÇöÀå¿¡¼­ ƯÈ÷ Áß¿äÇÑ ¿ÜºÎ °Ë»ç½Ç ¹æ¹® ¹× ÈÄ¼Ó Áø·á ¿¹¾àÀÇ Çʿ伺À» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. Áï°¢ÀûÀÎ °á°ú Á¦°øÀº ȯÀÚÀÇ ¸¸Á·µµ¸¦ ³ôÀ̰í, Áï½Ã Ä¡·á¸¦ ½ÃÀÛÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.

ÀÏÂ÷ÀÇ·á ÇöÀåÀ» Áö¿øÇÏ´Â Áø´Ü ±â¼úÀº ¾î¶»°Ô ÁøÈ­Çϰí ÀÖÀ»±î?

ÃֽŠÀÇ»ç Áø·á½Ç Áø´ÜÀº ÃÖ¼ÒÇÑÀÇ »ùÇà Á¶Á¦·Î Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇÏ´Â ÄÄÆÑÆ®ÇÏ°í »ç¿ëÇϱ⠽¬¿î ±â±â¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ÇöÀç POC °Ë»ç Ç÷§Æû¿¡´Â ¸é¿ª ÃøÁ¤¹ý, ºÐÀÚÁø´Ü¹ý, ¼Ò±Ô¸ð Áø·á¼Ò¸¦ À§ÇØ ¼³°èµÈ µðÁöÅÐ ¿µ»ó Áø´Ü µµ±¸°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¹«¼± ¿¬°áÀÌ °¡´ÉÇÑ ÀÚµ¿ ºÐ¼®±â´Â ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÏ°í ¹®¼­È­ Ç¥ÁØÀ» ÁؼöÇϱâ À§ÇØ Ã¤ÅõǾú½À´Ï´Ù.

¿þ¾î·¯ºí Áø´Ü±â±â¿Í ÈÞ´ë¿ë ÃÊÀ½ÆÄ Áø´Ü±â±âµµ ÀÏÂ÷ Áø·á¿¡ µµÀÔµÇ¾î °Ë»ç ´É·ÂÀÇ È®´ë°¡ °¡´ÉÇØÁ³½À´Ï´Ù. Ŭ¶ó¿ìµå¿¡ ¿¬°áµÈ Áø´Ü Ç÷§ÆûÀº ÀüÀÚ ÀÇ·á ±â·Ï(EHR)°úÀÇ µ¥ÀÌÅÍ ÅëÇÕÀ» ¿ëÀÌÇÏ°Ô Çϰí, Áø·áÀÇ ¿¬¼Ó¼º°ú Áý´Ü °Ç°­ ÃßÀûÀ» Çâ»ó½Ãŵ´Ï´Ù. Ãø¸é È帧 ±â¼ú, ¹Ì¼¼À¯Ã¼ °øÇÐ, ¸ÖƼÇ÷º½º °Ë»çÀÇ ¹ßÀüÀ¸·Î Áø´Ü ¼Óµµ¿Í Á¤È®µµ°¡ ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

ä¿ëÀÌ È®´ëµÇ´Â °÷Àº ¾îµðÀ̸ç, ¾î¶² °Ë»ç Ä«Å×°í¸®°¡ °¡Àå Ȱ¹ßÇѰ¡?

ÀÇ»ç Áø·á½Ç Áø´ÜÀº °¡Á¤ ÀÇ·á, ³»°ú, ¼Ò¾Æ°ú, ÀÀ±Þ ÀÇ·á¿¡¼­ ³Î¸® »ç¿ëµË´Ï´Ù. ƯÈ÷ ¸¸¼ºÁúȯ °ü¸®, °¨¿° °¨Áö, ½ÉÇ÷°ü À§Çè ¸ð´ÏÅ͸µÀ» Áö¿øÇÏ´Â °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô½À´Ï´Ù. ¿©±â¿¡´Â HbA1c, ÁöÁú ÆÐ³Î, ¿¬¼â»ó±¸±Õ °Ë»ç, µ¶°¨ ¹× COVID-19 °Ë»ç, ¼Òº¯ °Ë»ç, ½ÉÀüµµ µîÀÌ Æ÷ÇԵ˴ϴÙ.

ºÏ¹Ì´Â ÀÏÂ÷ÀÇ·áÀÇ ³ôÀº ¼öÁØÀÇ ÀÎÇÁ¶ó¿Í »óȯ Áö¿øÀ¸·Î ÀÎÇØ ¿©ÀüÈ÷ °¡Àå Å« ½ÃÀåÀ¸·Î ³²¾Æ ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÏÂ÷ÀÇ·áÁ¦µµ°¡ È®´ëµÇ°í ÀÖ´Â À¯·´°ú ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­µµ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¿¹¹æ °ËÁø ¹× ¸¸¼ºÁúȯ °ü¸®¸¦ °³¼±Çϱâ À§ÇÑ Á¤ºÎÀÇ ³ë·Âµµ »ç¹«½Ç ±â¹Ý Áø·á ȯ°æ¿¡¼­ÀÇ Áø´Ü Á¢±ÙÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÀÇ»ç Áø·á½Ç Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

ÀÇ»ç Áø·á½Ç Áø´Ü ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº Áø·á ÇöÀå¿¡¼­ÀÇ ½Å¼ÓÇÑ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ¼ÒÇüÈ­ µÈ POC(Point-of-Care) ±â¼úÀÇ ¹ßÀüÀÔ´Ï´Ù. ÀÚµ¿ºÐ¼®±â º¸±Þ, ÀüÀÚ ÀÇ·á ½Ã½ºÅÛ°úÀÇ ÅëÇÕ, Áúȯº° ½Å¼Ó °Ë»ç È®´ë µîÀÌ º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ÀÇ»çµéÀº Áø·á È¿À²¼ºÀ» ³ôÀ̰í, ȯÀÚ ´ë±â ½Ã°£À» ´ÜÃàÇϰí, Áø·á ¿¬°è¸¦ °³¼±Çϱâ À§ÇØ Áø´Ü¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¿¹¹æÀû °ËÁø ¹× ¸¸¼ºÁúȯ ¸ð´ÏÅ͸µÀ» Áö¿øÇÏ´Â Áø·áºñ º¸»ó ü°è´Â ½ÃÀåÀÇ ¾ÈÁ¤¼ºÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ȯÀÚ ¼ö°¡ Áõ°¡Çϰí Áï°¢ÀûÀÎ Áø·á¿¡ ´ëÇÑ ±â´ë°¡ ³ô¾ÆÁü¿¡ µû¶ó, µµ½Ã¿Í Áö¹æÀÇ Áø·á ȯ°æ Àü¹Ý¿¡ °ÉÃÄ Áø·á½Ç ³» Áø´Ü¾à¿¡ ´ëÇÑ ¼ö¿ä´Â °è¼Ó Áõ°¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(POC(Point of Care) °Ë»ç ±â±â, ÀÓ»óÈ­ÇÐ ºÐ¼®±â, ¸é¿ªÃøÁ¤ ½Ã½ºÅÛ, ºÐÀÚÁø´Ü Àåºñ, ¼Òº¯ °Ë»ç ½Ã½ºÅÛ), ¿ëµµ(°¨¿°Áõ ¿ëµµ, ½ÉÇ÷°üÁúȯ ¿ëµµ, ´ë»çÁúȯ ¿ëµµ, ¾Ï Áø´Ü ¿ëµµ, ÀӽŠ¿ëµµ, ºÒÀÓ °Ë»ç ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Physician Office Diagnostics Market to Reach US$236.5 Million by 2030

The global market for Physician Office Diagnostics estimated at US$115.9 Million in the year 2024, is expected to reach US$236.5 Million by 2030, growing at a CAGR of 12.6% over the analysis period 2024-2030. Point-of-Care Testing Devices, one of the segments analyzed in the report, is expected to record a 14.6% CAGR and reach US$114.1 Million by the end of the analysis period. Growth in the Clinical Chemistry Analyzers segment is estimated at 10.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$31.6 Million While China is Forecast to Grow at 17.3% CAGR

The Physician Office Diagnostics market in the U.S. is estimated at US$31.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$50.6 Million by the year 2030 trailing a CAGR of 17.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.0% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.0% CAGR.

Global Physician Office Diagnostics Market - Key Trends & Drivers Summarized

Why Are In-Office Diagnostics Gaining Preference Among Providers and Patients?

Physician office diagnostics encompass a wide range of tests conducted during a routine visit, allowing timely diagnosis and treatment decisions. These include blood tests, urinalysis, ECGs, imaging, rapid antigen tests, and point-of-care analyzers. The convenience of conducting diagnostics on-site improves clinical efficiency, patient compliance, and diagnostic turnaround times.

Physicians are increasingly investing in diagnostic tools for conditions such as diabetes, respiratory infections, cardiovascular disease, and sexually transmitted infections. These tools help reduce the need for external lab visits and follow-up appointments, particularly important in primary care and urgent care settings. The ability to deliver immediate results enhances patient satisfaction and enables same-day treatment initiation.

How Are Diagnostic Technologies Evolving to Support Primary Care Settings?

Modern physician office diagnostics focus on compact, user-friendly devices that offer accurate results with minimal sample preparation. Point-of-care testing platforms now include immunoassays, molecular diagnostics, and digital imaging tools designed for small practice environments. Automated analyzers with wireless connectivity are being adopted to streamline workflow and ensure compliance with documentation standards.

Wearable diagnostics and portable ultrasound devices are also entering primary care practices, enabling expanded examination capabilities. Cloud-connected diagnostic platforms facilitate data integration with electronic health records (EHRs), improving continuity of care and population health tracking. Advances in lateral flow technology, microfluidics, and multiplex testing are further enhancing diagnostic speed and precision.

Where Is Adoption Expanding and Which Test Categories Are Most Active?

Physician office diagnostics are widely used across family medicine, internal medicine, pediatrics, and urgent care. Demand is particularly high for tests that support chronic disease management, infectious disease detection, and cardiovascular risk monitoring. These include HbA1c, lipid panels, strep tests, flu and COVID-19 testing, urinalysis, and ECGs.

North America remains the largest market due to advanced primary care infrastructure and reimbursement support. However, adoption is growing in Europe and Asia-Pacific, where primary care systems are expanding. Government initiatives to improve preventive screening and chronic disease management are also promoting diagnostic access in office-based care environments.

Growth in the Physician Office Diagnostics market is driven by several factors…

Growth in the physician office diagnostics market is driven by the rising demand for rapid, in-practice diagnostic testing, increasing prevalence of chronic diseases, and advances in compact, point-of-care technologies. Broader use of automated analyzers, integration with electronic health systems, and expansion of disease-specific rapid tests are supporting adoption.

Physicians are also investing in diagnostics to enhance practice efficiency, reduce patient wait times, and improve care coordination. Reimbursement frameworks that support preventive screenings and chronic condition monitoring are strengthening market stability. As patient volume grows and expectations for immediate care rise, demand for in-office diagnostics is set to continue increasing across urban and rural care settings.

SCOPE OF STUDY:

The report analyzes the Physician Office Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Point-of-Care Testing Devices, Clinical Chemistry Analyzers, Immunoassay Systems, Molecular Diagnostics, Urinalysis Systems); Application (Infectious Diseases Application, Cardiovascular Disorders Application, Metabolic Disorders Application, Cancer Diagnosis Application, Pregnancy Application, Fertility Testing Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â